RosenR.C., FisherW.A., EardleyI., NiederbergerC., NadelA., SandM.Men's Attitudes to Life Events and Sexuality (MALES) Study. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin, 2004; 20(5):607–617.
2.
LericheR.Des obliterations arterielles hautes comme cause d’une insuffuissance circulatoire des members inferieures. Bull Soc Chir Paris, 1923; 49:1404.
3.
KupelianV., ShabsighR., AraujoA.B., O’DonnellA.B., McKinlayJ.B.Erectile dysfunction as a predictor of the metabolic syndrome in aging men: results from the Massachusetts Male Aging Study. J Urol, 2006; 176(1):222–226.
SalemA., KendirciM., HellstromW.J.Udenafil, a long-acting PDE5 inhibitor for erectile dysfunction. Curr Opin Investig Drugs, 2006; 7(7):661–669.
6.
KaufmanJ.M., DietrichJ.W.Safety and efficacy of avanafil, a new phosphodiesterase type 4 inhibitor for treating erectile dysfunction. J Urol, 2006; 174(Suppl 4):299 (Abstract 923).
7.
PrinceW., CampbellA.S., TongW., et al.SLX-2102, a new long-acting PDE5 inhibitor: preliminary safety, tolerability, PK and endothelial function effects in healthy subjects. J Urol, 2006; 174(Suppl 4):299(Abstract 924).
McMahonC.Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on demand tadalafil. J Sex Med, 2004; 1:58–65.
10.
McVaryK.T.Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol, 2005; 47(6):838–845.
11.
MulhallJ.P., LandS., ParkerM., et al.The use of an erectogenic pharmacotheraphy regimen following radical prostatectomy improves recovery of spontaneous erectile function. J Sex Med, 2005; 2:532–542.
12.
MelmanA., Bar-ChamaN., McCulloughA., DaviesK., ChristG.The first human trial for gene transfer therapy for the treatment of erectile dysfunction: preliminary results. Eur Urol, 2005; 48(2):314–318.
